Forward Looking Statement Risks and uncertainties include, but are not limited to our dependence on a principal product platform; the impact of competitive products, technological change and product innovation; our ability to maintain an effective sales force and expand our distribution network; our ability to maintain and grow our customer base; our ability to scale the business to support revenue growth; our ability to secure and retain adequate coverage or reimbursement from third-party payors; the impac ...

Insulet Corporation (NASDAQ:PODD) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President and Chief Executive Officer Ana Maria Chadwick - Executive Vice President, Chief Financial Officer and Treasurer Conference Call Participants Margaret Kaczor - William Blair Robbie Marcus - JP Morgan Jeff Johnson - Baird Michael Polark - Wolfe Research Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Patric ...

Insulet (PODD) reported $441.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 23.4%. EPS of $0.73 for the same period compares to $0.23 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $423.52 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +87.18%, with the consensus EPS estimate being $0.39.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ho ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2024 OR Washington, D.C. 20549 _____________________________________________________ Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-33462 ___________________________________________________________ INSULET CORPORATION (Exact name of ...

Exhibit 99.1 Insulet Reports First Quarter 2024 Revenue Increase of 23% Year-Over-Year Raising Full Year Revenue and Operating Margin Guidance ACTON, Mass. - May 9, 2024 - Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced financial results for the three months ended March 31, 2024. ® First Quarter Financial Highlights: Recent Strategic Highlights: See description of non-GAAP financial measure ...

Analysts on Wall Street project that Insulet (PODD) will announce quarterly earnings of $0.39 per share in its forthcoming report, representing an increase of 69.6% year over year. Revenues are projected to reach $423.52 million, increasing 18.3% from the same quarter last year.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this perio ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.It also includes access to the Zacks Style Scores.What ar ...

Insulet (PODD) closed the most recent trading day at $166.19, moving +1.23% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.02%. Elsewhere, the Dow gained 0.4%, while the tech-heavy Nasdaq added 2.03%.The the stock of maker of insulin infusion systems has fallen by 4.22% in the past month, leading the Medical sector's loss of 5.2% and undershooting the S&P 500's loss of 3.15%.The upcoming earnings release of Insulet will be of great interest to investors. The company's ea ...

Insulet (PODD) is scheduled to report first-quarter 2024 results on May 9 after market close.In the last reported quarter, the company’s adjusted earnings per share of $1.40 surpassed the Zacks Consensus Estimate by a remarkable 108.96%. Earnings beat estimates in each of the trailing four quarters, the average beat being 100.09%.Let’s take a look at how things have shaped up prior to this announcement.Factors at PlayIn 2023, Insulet firmly established itself as the market leader in automated insulin delive ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Insulet (PODD) , which belongs to the Zacks Medical - Products industry, could be a great candidate to consider.This maker of insulin infusion systems has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 93.23%.For the last repor ...